NASDAQ
TG Therapeutics, Inc. (NASDAQ: TGTX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the five research firms that are currently covering the company, Marketbeat.com repor...
NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the 8th ...
Advantage Alpha Capital Partners LP lowered its stake in shares of TG Therapeutics, Inc. (NASDAQ: TGTX) by 30.5% in the second quarter, according to its most recent Form 13F filing with the Securities...
Creative Planning lessened its stake in TG Therapeutics, Inc. (NASDAQ: TGTX) by 8.5% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owne...
TG Therapeutics continues strong execution with Briumvi, maintaining beat-and-raise performance and robust financials, including a new $100 million buyback program. However, high investor expectations...
TGTX has seen rapid enrolment of the ENHANCE study which could allow a simplified dosing regime of IV Briumvi. A readout is possible for mid-2026. Investors may need to wait longer for the subcutaneou...
Roche presented "unprecedented" test results for its multiple sclerosis treatment, putting pressure on key rival TG Therapeutics....
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage....
TG Therapeutics beats third-quarter estimates as a surge in Briumvi sales drives revenues up 92.8% and leads to a higher 2025 outlook....
TG Therapeutics, Inc. reported strong Q3 results, with Briumvi revenues up 84% year-over-year and full-year guidance raised to $585 million. TGTX continues to expand Briumvi's market presence, driven ...
No price data available for this timeframe.